In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
ABT-492 exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs (in micrograms per milliliter) at which 90% of the isolates tested were inhibited as follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008; and Streptococcus pneumoniae, 0.015. It was four- to sixfold more active than other fluoroquinolones, including against levofloxacin-resistant strains of S. pneumoniae, methicillin-resistant Staphylococcus aureus, and Prevotella species.
Goldstein
Ellie J C
EJ
RM Alden Research Laboratory, Santa Monica, California 90404, USA. EJCGMD@aol.com
Citron
Diane M
DM
Merriam
C Vreni
CV
Warren
Yumi A
YA
Tyrrell
Kerin L
KL
Fernandez
Helen T
HT
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001420:Bacteria, Aerobic / Q000187:drug effects*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D010256:Paranasal Sinuses / Q000382:microbiology*; D015363:Quinolones / Q000494:pharmacology*; D012852:Sinusitis / Q000382:microbiology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C477891:delafloxacin